Fibroscan® Medical Device, Assessment for Non Invasive Diagnosis of Liver Steatosis
Fibroscan® Medical Device, Assessment for Non Invasive Diagnosis of Liver Steatosis
Hypothesis of this study is the existence of a relation between parameters measured by FibroScan® FS 502 according to our non invasive method and liver steatosis condition.
This proof of concept validation is made up of two steps:
Experimental procedures consist in:
Diagnosis of liver lipid overload (named liver steatosis), unrelated to alcohol consumption, still mainly based on histological exam of the liver. An histological continuity exists going from clean liver steatosis (Non Alcoholic Fatty Liver Disease, NAFLD) to steatohepatitis with signs of inflammation and tissue fibrosis (Non Alcoholic Steato-Hepatitis, NASH). It's now well-known that disease can evolve to cirrhosis and its complications.
Hypothesis of this study is the existence of a relation between parameters measured by FibroScan® FS 502 according to our non invasive method and liver steatosis condition.
This proof of concept validation is made up of two steps:
Measures on healthy volunteers enable to do an intra-operator reproductibility analysis, a study of an age effect and a search of potential mechanic aging of the liver.
Experimental procedures consist in:
The final aim of this study is to propose a device enable medical community to do in vivo hepatic rheology observation, highly correlated to liver lipid overload. After industrialization of this innovation, this diffusion could making easier patients follow-up.
Inclusion Criteria:
Healthy subjects - Steps 1 and 2
Patients with liver steatosis - Step 2
Exclusion Criteria:
Healthy subjects - Step 1
Healthy subjects - Step 2
Healthy subjects - Steps 1 and 2
Patients with liver steatosis - Step 2